News Article | November 29, 2016
QUINCY, MA--(Marketwired - November 29, 2016) - NuVal LLC, a company that analyzes the total nutritional value of food products on a scale of 1 to 100 (the higher the score, the better the nutrition), has launched two tools specifically designed to empower consumers with reliable information in order to make more nutritious food choices. The NuVal® Score Search platform provides direct access to the vast NuVal database of scores. The NuScan mobile app allows users to view NuVal Scores anytime, in any store. With these tools, consumers can identify and purchase more nutritious products for themselves and their families. The NuVal Score Search platform provides access to the most scrupulously managed, UPC-specific nutrient database in the world. Over 125,000 national brand and private label products have been scored to date. Created by an international team of leading experts, NuVal is the most comprehensive nutritional scoring system in existence. Over 30 macro and micronutrients are evaluated in the scoring process, as is nutrient density, macronutrient quality, and relevance to disease risk and health outcomes. Using NuVal's mobile app, NuScan, consumers can scan barcodes and see scores instantly. If a product is not found, users can submit product images to NuVal using the app, and will even receive a scoring certificate once processed. In addition, we also wanted to present the opportunity to give the gift of health to family and loved ones. For a limited time only, anyone can purchase a one-year gift subscription for family members or friends to any of the NuVal tools, and this gift subscription can be purchased at 15% of the original price. Launched in 2008, the NuVal Nutritional Scoring System can be found in over 1,600 retail grocery stores throughout the United States. During the last eight years, experts at leading institutions have conducted extensive validation and impact studies, and this research has repeatedly substantiated that the NuVal Scores: With the algorithm and scores fully validated and proven, NuVal is now opening the scoring database to a much broader audience. According to Dr. David Katz, inventor of the ONQI® algorithm that powers the NuVal Scoring System, "NuVal is the most robustly validated nutritional scoring system available. By providing nutrition transparency and encouraging people to "choose a higher number," NuVal empowers shoppers to make healthier decisions. In addition to expert research confirming the NuVal System works, we have heard from people who attribute losing more than 100lbs to NuVal guidance, and trading up their groceries. And now, with these on-line and mobile tools available to the public, coaches and shoppers are able to view the NuVal Scores, choose higher scoring options, and trade up to better nutrition and to better health." To register for a 30-day free trial of NuVal Empower (both tools in one convenient package), go to https://empower.nuvaldata.com/en-US/login.do. Register for Score Search or NuScan individually on the same page. To view the list of relevant published studies, email email@example.com. To learn more about NuVal LLC, visit nuval.com. NuVal LLC is a joint venture formed in 2008 by Topco Associates, LLC, and Griffin Hospital of Derby, Connecticut, a non-profit community hospital and home to the Yale-Griffin Prevention Research Center. Located in Quincy, MA, NuVal licenses its proprietary food scoring system, which is based on ONQI® (Overall Nutrition Quality Index) science, to food retailers across the country.
Bhardwaj S.,Griffin Hospital |
Coleman C.I.,University of Connecticut |
Coleman C.I.,Hartford Hospital |
Sobieraj D.M.,University of Connecticut |
Sobieraj D.M.,Hartford Hospital
American Journal of Health-System Pharmacy | Year: 2012
Purpose. The efficacy of statins in combination with interferon therapy in patients with multiple sclerosis (MS) is reviewed. Methods. A systematic literature search was conducted through September 2011 to identify randomized controlled trials that evaluated the effect of combination statin-interferon therapy compared with interferon therapy alone in patients with MS. Trials had to report at least one of the following outcomes of interest: clinical relapse rate, disease progression, or Expanded Disability Status Scale (EDSS) score. A random-effects model was used to pool data. Trial quality was assessed using the Jadad score. Results. Four unique trials were included in the analysis (n = 463 subjects; range of follow-up, 9-24 months), all with a Jadad score of e3. All trials evaluated patients with relapsing-remitting MS (RRMS). Most trials enrolled patients taking interferon beta therapy either twice or three times weekly. The mean baseline EDSS scores ranged from 1.2 to 3.4. Evaluated statins included simvastatin and atorvastatin. No significant difference was found between the statin and control groups in the incident rate ratio for clinical relapse (0.72; 95% confidence interval [CI], 0.17 to 3.11), risk of relapse (relative risk [RR], 0.99; 95% CI, 0.53 to 1.85], disease progression (RR, 1.31; 95% CI, 0.73 to 2.36), or difference in the change in the EDSS score from baseline (weighted mean difference, -0.06; 95% CI, -0.30 to 0.19). Conclusion. A meta-analysis revealed that the addition of statins to interferon therapy did not significantly influence the relapse risk, disease progression, or EDSS scores in patients with RRMS. Copyright © 2012, American Society of Health-System Pharmacists, Inc. All rights reserved.
Mahmood S.,Griffin Hospital |
Booker I.,University of Connecticut |
Huang J.,University of Connecticut |
Coleman C.I.,University of Connecticut
Journal of Clinical Psychopharmacology | Year: 2013
BACKGROUND: Clinical Antipsychotic Trials of Intervention Effectiveness showed that atypical antipsychotics (AAPs) were associated with significant weight gain and glucose intolerance. A few trials have shown topiramate to reduce weight gain in patients receiving AAPs, although this benefit has not been present in all trials. OBJECTIVE: This study aimed to determine topiramate therapy's impact on weight gain in patients receiving AAPs. DATA SOURCE: A systematic literature search of MEDLINE (1948 to July 8, 2011) and Cochrane CENTRAL (4th Quarter 2011) was conducted. STUDY SELECTION: Eight trials (n = 336 participants) met our inclusion criteria: randomized controlled trial, evaluated topiramate in patients taking AAPs, and reported weight change during the treatment course. DATA EXTRACTION: Two investigators (S.M. and C.I.C.) used a standardized data abstraction tool to independently collect data, with disagreement resolved through discussion. The difference between the mean weight in the topiramate and control groups was calculated as the weighted mean difference with accompanying 95% confidence interval. A random effect model was used for all analyses. DATA SYNTHESIS: Upon meta-analysis, we found that patients receiving topiramate lost weight or had attenuated weight gain compared to control patients (weighted mean difference,-2.83 kg; 95% confidence interval,-4.62 to-1.03). CONCLUSIONS: Our meta-analysis shows that using topiramate can prevent or reduce weight gain associated with AAPs. Copyright © 2013 Lippincott Williams &Wilkins.
Gnanaraj J.F.,Griffin Hospital |
Von Haehling S.,Charité - Medical University of Berlin |
Anker S.D.,Charité - Medical University of Berlin |
Anker S.D.,Center for Clinical and Basic Research |
And 2 more authors.
Kidney International | Year: 2013
Worsening renal function (WRF) during the treatment of acute decompensated heart failure (ADHF) occurs in up to a third of patients and is associated with worse survival. Venous congestion is increasingly being recognized as a key player associated with WRF in ADHF. Understanding the hemodynamic effects of venous congestion and the interplay between venous congestion and other pathophysiological factors such as raised abdominal pressure, endothelial cell activation, anemia/ iron deficiency, sympathetic overactivity, and stimulation of the renin-angiotensin-aldosterone system will help in devising effective management strategies. Early recognition of venous congestion through novel techniques such as bioimpedance measurements and remote monitoring of volume status combined with customized diuretic regimens may prevent venous congestion and perhaps avoid significant WRF. © 2012 International Society of Nephrology.
Bhardwaj S.,Griffin Hospital |
Selvarajah S.,Yale University |
Schneider E.B.,The Surgical Center
Clinical Interventions in Aging | Year: 2013
Statins have demonstrated substantial benefits in supporting cardiovascular health. Older individuals are more likely to experience the well-known muscle-related side effects of statins compared with younger individuals. Elderly females may be especially vulnerable to statin-related muscle disorder. This review will collate and discuss statin-related muscular effects, examine their molecular and genetic basis, and how these apply specifically to elderly women. Developing strategies to reduce the incidence of statin-induced myopathy in older adult women could contribute to a significant reduction in the overall incidence of statin-induced muscle disorder in this vulnerable group of patients. Reducing statin-related muscle disorder would likely improve overall patient compliance, thereby leading to an increase in improved short- and long-term outcomes associated with appropriate use of statins.
Lim L.S.,Griffin Hospital |
Haq N.,Griffin Hospital |
Mahmood S.,Griffin Hospital |
Hoeksema L.,Griffin Hospital
American Journal of Preventive Medicine | Year: 2011
Context: Atherosclerotic cardiovascular diseases, including coronary heart disease (CHD), carotid artery stenosis (CAS), peripheral artery disease (PAD), and abdominal aortic aneurysm (AAA), affect millions of U.S. adults and are leading causes of morbidity and mortality. There is some uncertainty regarding the utility of certain screening tests for prevention of cardiovascular morbidity and mortality. Evidence acquisition: Current guidelines and studies pertaining to CHD, CAS, PAD, and AAA screening in the adult population were reviewed. Evidence synthesis: CHD risk can be estimated by the Framingham Risk Score (FRS), which is valuable in identifying high-risk asymptomatic adults who may benefit from preventive treatments. There is moderate certainty that the benefits of screening do not outweigh the harms for individuals with asymptomatic CAS. The potential harms associated with routine PAD screening in asymptomatic adults are also likely to exceed benefits. Ultrasonography is a safe, noninvasive, and reliable screening test used to identify AAAs for treatment in men aged >65 years who have ever smoked. Conclusions: American College of Preventive Medicine (ACPM) recommends CHD risk assessment using the FRS to guide risk-based therapy. ACPM does not recommend routine screening of the general adult population using electrocardiogram, exercise-stress testing, computed tomography scanning, ankle-brachial index, carotid intima medial thickness, or emerging risk factors, including high-sensitivity C-reactive protein (hs-CRP). ACPM does not recommend routine screening of the general adult population for CAS or PAD. ACPM recommends one-time AAA screening in men aged 65-75 years who have ever smoked. Routine AAA screening in women is not recommended. © 2011 American Journal of Preventive Medicine.
Muniraj T.,Yale University |
Muniraj T.,Griffin Hospital |
Barve P.,Yale University
North American Journal of Medical Sciences | Year: 2013
Pancreatic cancer is the tenth most common cancer and the fourth leading cause of cancer deaths in the United States. Surgery remains a cornerstone in the treatment of pancreatic cancer. Unfortunately, the percentage of patients presenting at the resectable stage is minimal. Although computed tomography (CT) scan remains the best modality to stage the tumor for resectability, laparoscopy and laparoscopic ultrasound offers its own advantages. Extended lymphadenectomy, portal vein resection, and arterial reconstruction have also been explored in multiple studies to enhance staging. The traditional pancreaticoduodenectomy (Whipple's procedure) with regional lymphadenectomy is still the standard of care in the surgical treatment of pancreatic cancer.
Lim L.S.,Griffin Hospital |
Kandavelou K.,Griffin Hospital |
Khan N.,Griffin Hospital
Journal of the American Geriatrics Society | Year: 2012
This is a comparison review of GeriaSims and Care of the Aging Medical Patient (CHAMP) modules addressing issues in palliative and hospice medicine found in the Portal of Geriatric Online Education, a free on-line repository of geriatric educational materials for medical educators. GeriaSims is a self-directed teaching module designed to systematically address many of the important questions involved in caring for individuals with chronic progressive and life-limiting illnesses. It is well suited for physicians, particularly medical residents and fellows in-training, who provide care for medically complicated elderly and terminally ill individuals. The CHAMP module is designed to familiarize physician educators with palliative and hospice medicine basics to teach residents and fellows through didactic slides, although it can probably be adapted for use by residents and fellows if audio commentary accompanies the slides. Both modules address practical approaches to addressing palliative care in patients and their families. They are useful teaching tools that address an important learning need and can be readily used to supplement current residency curriculum in hospice and palliative medicine. © 2012, Copyright the Authors Journal compilation © 2012, The American Geriatrics Society.
Monica Reddy R.P.,Griffin Hospital |
Inzucchi S.E.,Yale University
Endocrine | Year: 2016
The glucose-lowering pharmacopeia continues to grow for patients with type 2 diabetes. The latest drug category, the SGLT2 inhibitors reduce glycated hemoglobin concentrations by increasing urinary excretion of glucose. They are used mainly in combination with metformin and other antihyperglycemic agents, including insulin. Their glucose-lowering potency is modest. Advantages include lack of hypoglycemia as a side effect, and mild reduction in blood pressure and body weight. Side effects include increased urinary frequency, owing to their mild diuretic action, symptoms of hypovolemia, genitourinary infections. There are also recent reports of rare cases of diabetic ketoacidosis occurring in insulin-treated patients. Recently, a large cardiovascular outcome trial reported that a specific SGLT2 inhibitor, empagliflozin, led to a reduction in the primary endpoint of major cardiovascular events. This effect was mainly the result of a surprising 38 % reduction in cardiovascular death, and the drug was also associated with nearly as large a reduction in heart failure hospitalization. These findings were notable because most drugs used in type 2 diabetes have not been shown to improve cardiovascular outcomes. Accordingly, there is growing interest in empagliflozin and the entire SGLT2 inhibitor class as drugs that could potentially change the manner in which we approach the management of hyperglycemia in patients with type 2 diabetes. © 2016, Springer Science+Business Media New York.
Griffin Hospital | Date: 2012-10-26
A method for evaluating a diet includes the steps of: inputting information about a plurality of individual foods forming the diet being evaluated into at least one of a computer and a database; evaluating the diet by measuring the quality of the individual foods forming the diet and compiling scores for each of said measured individual foods to generate an overall score for the diet, wherein the evaluating and compiling step is performed by the computer; and providing information to an individual about overall healthiness of the diet being evaluated.